The mechanisms of anticancer agents by genistein and synthetic derivatives of isoflavone

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 4, 2012, Pages 350-362

  Li, H Q ^a   Luo, Y ^a   Qiao, C H ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Anticancer; Derivative; Genistein; Isoflavone; Molecular mechanisms; Signaling pathways

Indexed keywords

3 FORMYLCHROMONE; BUTEIN; CHROMENE DERIVATIVE; CISPLATIN; DAIDZEIN; GENISTEIN; I KAPPA B; PROTEIN KINASE B; QUERCETIN; TANNIN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANEMIA; ANGIOGENESIS; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PREVENTION; CELL CYCLE; CELL CYCLE REGULATION; CELL SURVIVAL; DIARRHEA; GENE CONTROL; GENE EXPRESSION; HUMAN; HYPOMAGNESEMIA; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; METASTASIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PERIPHERAL NEUROPATHY; PROSTATE CANCER; SOYBEAN; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GENISTEIN; HUMANS; ISOFLAVONES; NEOPLASMS;

EID: 84863344225     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712799829258     Document Type: Article

References (152)

1. Kanadaswami, C.; Lee, L. T.; Lee, P. P.; Hwang, J. J.; Ke, F. C.;Huang, Y. T.; Lee, M. T. The antitumor activities of flavonoids. In vivo, 2005, 19, 895-909.
2. Ren, W.; Qiao, Z.; Wang, H.; Zhu, L.; Zhang, L. Flavonoids: promising anticancer agents. Med. Res. Rev., 2003, 23, 519-534.
3. Dimmock, J. R.; Elias, D. W.; Beazely, M. A.; Kandepu, N. M. Bioactivities of chalcones. Curr. Med. Chem., 1999, 6, 1125-1149.
4. Horvathova, K.; Vachalkova, A.; Novotny, L. Flavonoids as chemoprotective agents in civilization diseases. Neoplasma, 2001,48, 435-441.
5. Kelloff, G.; Boone, C.; Crowell, J.; Steele, V.; Lubet, R.; Sigman, C. Chemopreventive drug development: Perspectives and progress. Cancer. Epidemiol. Biomarkers. Prev., 1994, 3, 85-98.
6. Adlercreutz, C.; Goldin, B.; Gorbach, S.; Hockerstedt, A.; Watanabe, S.; Hamalainen, E.; Markkanen, H.; Makela, T.; Wahala, K.; Adlercreutz, T. Soybean phytoestrogen intake and cancer risk. J. Nutr.,1995, 125, 757-770.
7. Hebert, J.; Hurley, G.; Olendzki, C.; Teas, J.; Ma, Y.; Hampl, S. Nutritional and socioeconomic factors in relation to prostate cancer mortality: A cross-national study. J. Natl. Cancer. Inst., 1998, 90, 1637-1647.
8. Jacobsen, K.; Knutsen, F.; Fraser, E. Does high soy milk intake reduce prostate cancer incidence? The Adventist health study (United States). Cancer. Cause. Control., 1998, 9, 553-557.
9. Adlercreutz, H. Does fiber-rich food containing animal lignan precursors protect against both colon and breast cancer? An extension of the 'fiber hypothesis', Gastroenterology, 1984, 86, 761-764.
10. Dewick, P.M. In The Flavonoids, Advances in Research Since 1986; Chapman and Hall: London, 1994.
11. Dixon, R.A. Isoflavonoids: biochemistry, molecular biology, and biological functions. In Comprehensive Natural Products Chemistry, Elsevier: Amsterdam, 1999.
12. Dixon, R. A.; Ferreira, D. Genistein. Phytochemistry., 2002, 60, 205-211.
13. Grynkiewicz, G. Synthetic Genistein as a Prospective Active Ingredient for Nutrition and Medicine. Pol. J. Food. Nutr. Sci., 2002, 11, 99-105.
14. WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr. Cancer., 1998, 32, 123-131.
15. Li, Y.; Upadhyay, S.; Bhuiyan, M.; Sarkar, F. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene., 1999,18, 3166-3172.
16. Li, Y.; Bhuiyan, M.; Sarkar, F. Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int J Oncol.,1999,15, 525-533.
17. WAF1upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr. Cancer., 1998, 31, 184-191.
18. Alhasan, S. A.; Pietrasczkiwicz, H.; Alonso, M. D.; Ensley, J.; Sarkar, F. H. Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr. Cancer., 1999, 34, 12-19.
19. (WAF1), Clin. Cancer. Res., 2001, 7, 1782-1789.
20. Spinozzi, F.; Pagliacci, M. C.; Migliorati, G.; Moraca, R.; Grignani, F.; Riccardi, C.; Nicoletti, I. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk. Res., 1994, 18, 431-439.
21. Constantinou, A.; Huberman, E. Genistein as an inducer of tumor cell differentiation: Possible mechanisms of action. Proc. Soc. Exp. Biol. Med., 1995, 208, 109-115.
22. Kupelian, P.; Katcher, J.; Levin, H.; Zippe, C.; Klein, E. Correlation of clinical and pathologic factors with rising prostatespecific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology, 1996, 48, 223-228.
23. Sato, N.; Gleave, M. E.; Bruchovsky, N.; Rennie, P. S.; Goldenberg, S. L.; Lange, P. H.; Sullivan, L. D. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.J. SteroidBiochem. Mol. Biol., 1996, 58, 139-146.
24. Richter, F.; Huang, H. F.; Li, M. T.; Danielpour, D.; Wang, S. L.; Irwin. R. J. Retinoid and androgen regulation of cell growth, epidermal growth factor and retinoic acid receptors in normal and carcinoma rat prostate cells. Mol. Cell. Endocrinol., 1999, 153, 29-38
25. Montgomery, J. S.; Price, D. K.; Figg, W. D. The androgen receptor gene and its influence on the development and progression of prostate cancer. J. Pathol., 2001, 195, 138-146
26. Kupelian, P.; Katcher. J.; Levin, H.; Zippe, C.; Klein, E. Correlation of clinical and pathologic factors with rising prostatespecific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology, 1996, 48, 249-260
27. Luke, M. C.; Coffey, D. S. Human androgen receptor binding to the androgen response element of prostate specific antigen. J. Androl., 1994, 15, 41-51
28. Davis, J. N.; Kucuk, O.; Sarkar, F. H. Expression of prostatespecific antigen is transcriptionally regulated by genistein in prostate cancer cells. Mol. Carcinog., 2002, 34, 91-101.
29. Po, L. S.; Chen, Z. Y.; Tsang, D. S.; Leung, L. K. Baicalein and genistein display differential actions on estrogen receptor (ER) transactivation and apoptosis in MCF-7 cells. Cancer. Lett., 2002, 187, 33-40.
30. Ho, S. M. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J. Cell. Biochem., 2004, 91, 491-503
31. Krege, J. H.; Hodgin, J. B.; Couse, J. F.; Enmark, E.; Warner, M.; Mahler, J. F. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc. Natl. Acad. Sci. USA., 1998, 95, 15677-15682
32. Weihua, Z.; Makela, S.; Andersson. LC.; Salmi. S.; Saji. S.; Webster, J. I. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc. Natl. Acad. Sci. USA., 2001, 98, 6330-6335
33. Cheng, J.; Lee, E. J.; Madison, L. D.; Lazennec, G. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS. Lett., 2004, 566,169-172
34. Zhu, X.; Leav, I.; Leung, Y. K.; Wu, M.; Liu, Q.; Gao, Y. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am. J. Pathol., 2004, 164, 2003-2012
35. Linja, M. J.; Savinainen, K. J.; Tammela, T. L.; Isola, J. J.; Visakorpi, T. Expression of ERalpha and ERbeta in prostate cancer. Prostate., 2003, 55, 180-186
36. Lau, K. M.; LaSpina, M.; Long, J.; Ho, S. M. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer. Res., 2000, 60, 3175-3182
37. Kim, I. Y.; Seong, D. H.; Kim. B, C.; Lee, D. K.; Remaley, A. T.; Leach, F. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgenindependent pathway. Cancer. Res., 2002, 62, 3649-3653.
38. Kim, I. Y.; Kim, B. C.; Seong, H.; Lee, D. K.; Seo, J. M.; Hong, Y. J. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer. Res., 2002, 62, 5365-5369.
39. Bektic, J.; Berger, A. P.; Pfeil, K.; Dobler, G.; Bartsch, G.; Klocker. H. Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta. Eur. Urol., 2004, 45, 245-251.
40. Bemis, D. L.; Capodice, J. L.; Desai, M.; Buttyan, R.; Katz, A. E. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo. Clin. Cancer. Res., 2004, 10, 5282-5292.
41. Zhou, J. R.; Gugger, E. T.; Tanaka, T.; Guo Y.; Blackburn, G. L.; Clinton, S. K. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J. Nutr., 1999, 129, 1628-1635.
42. Aronson, W. J.;Tymchuk, C. N.; Elashoff, R. M.; McBride, W. H.; McLean, C.; Wang, H. Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr. Cancer., 1999, 35, 130-136.
43. Fritz, W. A.; Wang, J.; Eltoum, I. E.; Lamartiniere, C. A: Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol. Cell. Endocrinol., 2002, 186, 89-99.
44. Wang, J.; Eltoum, I. E.; Lamartiniere, C. A. Dietary genistein suppresses chemically induced prostate cancer in Lobund-Wistar rats. Cancer. Lett., 2002, 186, 11-18.
45. Mentor-Marcel, R.; Lamartiniere, C. A.; Eltoum, I. E.; Greenberg, N. M.; Elgavish, A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer. Res.,2001, 61, 6777-6782.
46. Hussain, M.; Banerjee, M.; Sarkar, F. H.; Djuric, Z.; Pollak, M. N.; Doerge, D. Soy isoflavones in the treatment of prostate cancer. Nutr. Cancer., 2003, 47, 111-117.
47. White, R. W.; Hackman, R. M.; Soares, S. E.; Beckett, L. A.; Li, Y.; Sun, B. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology., 2004, 63, 259-263.
48. Messina, M. J. Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr Rev, 2003, 61,117-131.
49. Lee, M. M.; Gomez, S. L.; Chang, J. S.; Wey, M.; Wang, R. T.; Hsing, A. W. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer. Epidemiol. Biomarkers. Prev., 2003, 12, 665-668.
50. Ozasa, K.; Nakao, M.; Watanabe, Y.; Hayashi, K.; Miki, T.; Mikami, K. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer. Sci., 2004, 95, 65-71.
51. Akiyama, T.; Ishida, J.; Nakagawa, S.; Ogawara, H.; Watanabe, S.; Itoh, N.; Shibuya, M.; Fukami, Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 1987, 262, 5592-5595.
52. Hunter, T. A thousand and one protein kinases. Cell., 1987, 50, 823-829.
53. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell., 1990, 61, 203-212.
54. Fotsis, T.; Pepper, M.; Adlercreutz, H.; Hase, T.; Montesano, R.; Schweigerer, L. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J. Nutr.,1995, 125, 790-797.
55. Barnes, S. Effect of genistein on in vitro and in vivo models of cancer. J. Nutr., 1995, 125, 777-783.
56. Constantinou, A.; Kiguchi, K.; Huberman, E. Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer. Res., 1990, 50, 2618-2624.
57. Peterson, G.; Barnes, S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate., 1993, 22, 335-345.
58. Peterson, G.; Barnes, S. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell. Growth. Differ., 1996, 7, 1345-1351.
59. Buckley, A. R.; Buckley, D. J.; Gout, P. W.; Liang, H.; Rao, Y. P.; Blake, M. J. Inhibition by genistein of prolactin-induced Nb2 lymphoma cell mitogenesis. Mol. Cell. Endocrinol., 1993, 98, 17-25.
60. Schweigerer, L.; Christeleit, K.; Fleischmann, G.; Adlercreutz, H.; Wahala, K.; Hase, T.; Schwab, M.; Ludwig, R.; Fotsis, T. Identification in human urine of a natural growth inhibitor for cells derived from solid paediatric tumours. Eur. J. Clin. Invest., 1992, 22, 260-264.
61. Matsukawa, Y.; Marui, N.; Sakai, T.; Satomi, Y.; Yoshida, M.; Matsumoto, K.; Nishino, H.; Aoike, A. Genistein arrests cell cycle progression at G2-M. Cancer. Res., 1993, 53, 1328-1331.
62. Fazlul, H. Sarkar, Li, Y. W. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer. Metast. Rev., 2002, 21, 265-280.
63. Kim, J. H.; Kang, J. W.; Kim, B. S.; Park, Y. S.; Jung, K. Y.; Yoon, D. Y. The apoptptic effects of the flavonoids N101-2 in human cervical cancer cells. Toxicol. In. Vitro., 2011, doi:10.1016/j.tiv.2011.10.012.
64. WAF1upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr. Cancer., 1998, 31, 184-191.
65. Alhasan, S. A.; Ensley, J. F.; Sarkar, F. H. Genistein induced molecular changes in a squamous cell carcinoma of the head and neck cell line. Int. J. Oncol., 2000, 16, 333-338.
66. Chiarugi, V.; Magnelli, L.; Cinelli, M.; Basi, G. Apoptosis and the cell cycle. Cell. Mol. Biol. Res., 1994, 40, 603-612.
67. Huang, P.; Ballal, K.; Plunkett, W. Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis. Cancer. Res., 1997, 57, 3407-3414.
68. Fisher, D. E. Apoptosis in cancer therapy: Crossing the threshold. Cell., 1994, 78, 539-542.
69. Spinozzi, F.; Pagliacci, M. C.; Migliorati, G.; Moraca., R.; Grignani, F.; Riccardi, C.; Nicoletti, I. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk. Res., 1994, 18, 431-439.
70. Kyle, E.; Neckers, L.; Takimoto, C.; Curt. G.; Bergan, R. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol. Pharmacol., 1997, 51, 193-200.
71. Findley, H. W.; Gu, L.; Yeager, A. M.; Zhou, M. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood, 1997, 89, 2986-2993.
72. Kane, D. J.; Sarafian, T. A.; Anton, R.; Hahn, H.; Gralla, E. B.; Valentine, J. S.; Ord, T.; Bredesen, D. E. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science., 1993, 262, 1274-1277.
73. Vogelstein, B.; Kinzler, K. W. p53 function and dysfunction. Cell, 1992, 70, 523-526.
74. Deiry, W. S.; Tokino, T.; Velculescu, V. E.; Levy, D. B.; Parsons, R.; Trent, J. M.; Lin, D.; Mercer, W. E.; Kinzler, K. W.; Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 1993, 75, 817-825.
75. Harper, J. W.; Adami, G. R.; Wei, N.; Keyomarsi, K.; Elledge, S. J: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 1993, 75, 805-816.
76. Agarwal, M. L.; Agarwal, A.; Taylor, W. R.; Stark, G. R. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA., 1995, 92, 8493-8497.
77. Xiong, Y.; Hannon, G. J.; Zhang, H.; Casso, D.; Kobayashi, R.; Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature., 1993, 366, 701-704.
78. WAF1/CIP1 induction, G2/M arrest, and apoptosis. J. Cell. Biochem., 1998, 69, 44-54.
79. Wang, T. T.; Sathyamoorthy, N.; Phang, J. M. Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis., 1996, 17, 271-275.
80. Wang, C.; Kurzer, M. S. Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr. Cancer., 1997, 28, 236-247.
81. Li, Y.; Upadhyay, S.; Bhuiyan, M.; Sarkar, F. H. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene., 1999, 18: 3166-3172.
82. Li, Y.; Bhuiyan, M.; Sarkar, F. H. Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int. J. Oncol., 1999, 15, 3, 525-533.
83. WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr. Cancer, 1998, 31, 184-19.
84. Kazi, A.; Daniel, K. G.; Smith, D. M.; Kumar, N. B.; Dou, Q. P. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem. Pharmacol., 2003, 66, 965-976.
85. Katdare, M.; Osborne, M.; Telang, N. T. Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells. Int. J. Oncol., 2002, 21,809-815.
86. Tophkhane, C.; Yang, S.; Bales, W.; Archer, L.; Osunkoya, A.; Thor, A. D.; Yang, X. Bcl-2 overexpression sensitizes MCF-7 cells to genistein by multiple mechanisms. Int. J. Oncol., 2007, 31, 967-874.
87. Su, S. J.; Chow, N. H.; Kung, M. L.; Hung, T. C.; Chang, K. L. Effects of Soy Isoflavones on Apoptosis Induction and G2-M Arrest in Human Hepatoma Cells Involvement of Caspase-3 Activation, Bcl-2 and Bcl-XL Downregulation, and Cdc2 Kinase Activity. Nutr. Cancer, 2003, 45, 113-120.
88. Ferguson, P.; Kurowska, E.; Freeman, D. J.; Chambers, A. F.; Koropatnick, D. J. A flavonoid fraction from cranberry extract inhibits proliferation of human tumor cell lines. J. Nutr., 2004, 134, 1529-1535.
89. Sun, J.; Liu, R. H. Cranberry phytochemical extracts induce cell cycle arrest and apoptosis in human MCF-7 breast cancer cells. Cancer. Lett., 2006, 241, 124-134.
90. Ding, H. M.; Duan, W. R.; Zhu, W. G. p21 response to DNA damage induced by genistein and etoposide in human lung cancer cells. Biochem. Biophys. Res. Comm., 2003, 305, 950-956.
91. Gossner, G.; Choi, M.; Tan L. J. Genistein-induced apoptosis and autophagocytosis in ovarian cancer cell. Gynecol. Oncol., 2007, 105, 23-30.
92. Papavassiliou, A. G. Transcription factors: Structure, function, and implication in malignant growth. Anticancer. Res, 1995, 15, 891-894.
93. Sen, R.; Baltimore, D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell, 1986, 47, 921-928.
94. Verma, I. M.; Stevenson, J. K.; Schwarz, E. M.; Van, A, D.; Miyamoto, S. Rel/NF-kappa B/I kappa B family: Intimate tales of association and dissociation. Genes. Dev., 1995, 9, 2723-2735.
95. Thanos, D.; Maniatis, T. NF-kappa B: A lesson in family values. Cell, 1995, 80, 529-532.
96. Ghosh, G.; Duyne, G.; Ghosh, S.; Sigler, P. B. Structure of NFkappa B p50 homodimer bound to a kappa B site. Nature, 1995, 373, 303-310.
97. Muller, C. W.; Rey, F. A; Sodeoka, M.; Verdine, G. L.; Harrison, S.C. Structure of the NF-kappa B p50 homodimer bound to DNA. Nature, 1995, 373, 311-317.
98. Muller, C. W.; Harrison, S. C. The structure of the NF-kappa B p50: DNA-complex: A starting point for analyzing the Rel family. FEBS. Lett., 1995, 369, 113-117.
99. Chen, Z. J.; Parent, L.; Maniatis, T. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell, 1996, 84, 853-862.
100. Chen, Z.; Hagler, J.; Palombella, V. J.; Melandri, F.; Scherer, D.; Ballard, D.; Maniatis, T. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitinproteasome pathway. Genes. Dev, 1995, 9, 1586-1597.
101. Traenckner, E. B.; Pahl, H. L.; Henkel, T.; Schmidt, K. N.; Wilk, S.; Baeuerle, P.A. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NFkappa B activation in response to diverse stimuli. EMBO. J., 1995, 14, 2876-2883.
102. Pahl, H. L.; Baeuerle, P. A. Control of gene expression by proteolysis. Curr. Opin. Cell. Biol., 1996, 8, 340-347.
103. Lenardo, M. J; Baltimore, D. NF-kappa B: A pleiotropic mediator of inducible and tissue-specific gene control. Cell, 1989, 58, 227-229.
104. Baldwin, A. S, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol., 1996, 14, 649-683.
105. Wu, M.; Lee, H.; Bellas, R. E.; Schauer, S. L.; Arsura, M.; Katz, D.; FitzGerald, M. J.; Rothstein, T. L.; Sherr, D. H.; Sonenshein, G E. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO. J., 1996, 15, 4682-4690.
106. Van Antwerp, D. J; Martin, S. J.; Kafri, T.; Green, D. R.; Verma, I. M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science, 1996, 274, 787-789.
107. Beg, A. A; Sha, W. C.; Bronson, R. T.; Ghosh, S.; Baltimore, D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature, 1995, 376, 167-170.
108. Bian, X.; McAllister-Lucas, L. M.; Shao, F.; Schumacher, K. R.; Feng, Z.; Porter, A. G.; Castle, V. P.; Opipari, A. W., Jr. NF-κB Activation Mediates Doxorubicin-induced Cell Death in N-type Neuroblastoma Cells. J. Biol. Chem., 2001, 276, 48921-48929.
109. Chuang, S. E.; Yeh, P. Y.; Lu, Y. S.; Lai, G. M.; Liao, C. M.; Gao, M.; Cheng, A. L. Basal levels and patterns of anticancer druginduced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem. Pharmacol., 2002, 63, 9, 1709-1716.
110. Yeh, P. Y.; Chuang, S. E.; Yeh, K. H.; Song, Y. C.; Ea, C. K.; Cheng, A. L. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer druginduced NFκB activation. Biochem. Pharmacol., 2002, 63, 1423-1430.
111. Li, Y.; Ellis, K. L.; Ali, S.; El Rayes, B. F.; Nedeljkovic-Kurepa, A.; Kucuk, O.; Philip, P. A.; Sarkar, F. H. Apoptosis-Inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-[kappa]B in BxPC-3 pancreatic cancer cell line. Pancreas, 2004, 28, 4, 90-95.
112. Banerjee, S.; Zhang, Y.; Ali, S.; Bhuiyan, M.; Wang, Z.; Chiao, P.J.; Philip, P. A.; Abbruzzese, J.; Sarkar, F. H. Molecular Evidence for Increased Antitumor Activity of Gemcitabine by Genistein In vitro and In vivo Using an Orthotopic Model of Pancreatic Cancer. Cancer. Res., 2005,65, 4181-4190
113. Hwang, J. T.; Ha, J.; Park, O. J. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem. Biophys. Res. Commun.,2005, 332, 2, 433-440.
114. Ohigashi, H.; Murakami, A. Cancer prevention with food factors: Alone and in combination. Biofactors, 2004, 22, 49-55.
115. 3in DU145 human prostate cancer cells: Role of the direct inhibition of CYP24 enzyme activity. Mol. Cell Endocrinol., 2005, 241, 49-61.
116. Lin, A.; Karin, M. NF-kappaB in cancer: a marked target. Semin. Cancer. Biol., 2003; 13,107-14.
117. Sweeney, C.; Li, L.; Shanmugam, R.; Bhat-Nakshatri, P.; Jayaprakasan, V.; Baldridge, LA.; Gardner, T.; Smith, M.; Nakshatri, H.; Cheng, L. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin. Cancer. Res., 2004, 10, 5501-5507.
118. Shukla, S.; MacLennan, G. T.; Fu, P.; Patel, J.; Marengo, S. R.; Resnick, M. I.; Gupta, S: Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia,2004, 6, 390-400.
119. Vinita, S. G.; Hao, Z. L.; Sanjeev, B. Radiation-induced HIF-1 cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int. J. Cancer: 2009, 124, 7, 1675-1684.
120. Franke, T. F.; Kaplan, D. R.; Cantley, L. C. PI3K: Downstream AKT ion blocks apoptosis. Cell, 1997, 88, 435-437.
121. Burgering, B. M.; Coffer, P. J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature, 1995, 376, 599-602.
122. Franke, T. F.; Yang, S. I.; Chan, T. O.; Datta, K.; Kazlauskas, A.; Morrison, D. K.; Kaplan, D. R.; Tsichlis, P. N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF activated phosphatidylinositol 3-kinase. Cell, 1995, 81, 727-736.
123. Alessi, D. R.; Andjelkovic, M.; Caudwell, B.; Cron, P.; Morrice, N.; Cohen, P.; Hemmings, B. A: Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO. J.,1996, 15, 6541-6551.
124. Rommel, C.; Clarke, B. A.; Zimmermann, S.; Nunez, L.; Rossman, R.; Reid, K.; Moelling, K.; Yancopoulos, G. D.; Glass, D. J. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science, 1999, 286,1738-1741.
125. Romashkova, J. A.; Makarov, S. S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature, 1999, 401, 86-90.
126. Ozes, O. N.; Mayo, L. D.; Gustin, J. A.; Pfeffer, S. R.; Pfeffer, L. M.; Donner, D. B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature, 1999, 401, 82-85.
127. Jaffe, E. S.; Harris, N. L.; Stein, H.; Vardiman, J. W. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. World Health Organization Classification of Tumors. IARC Press:Lyon, 2001.
128. Morris, S. W.; Kirstein, M. N.; Valentine, M. B.; Dittmer, K.; Shapiro, D. N.; Look, A. T.; Saltman, D. L. Fusion of a kinase gene ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science, 1995, 267, 316-317.
129. Waggot, W.; Lo, Y. M. D.; Bastard, C.; Gatter, K. C.; Leroux, D.; Manson, D. Y.; Boultwood, J.; Wainscoat, J. S. Detection of NPMALK DNA rearrangement in CD30+ anaplastic large cell lymphoma. Br. J. Haematol., 1995, 89, 905-907.
130. Burgering, B. M. Ciffer, P. J: Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature, 1995, 376, 599-602.
131. Kuefer, M. U.; Look, A. T.; Pulford, K.; Behm, F. G.; Pattengale, P. K.; Manson, D. Y.; Morris, S. W. Retrovirus-mediated gene transfer to NPM-ALK causes lymphoid malignancy in mice. Blood, 1997, 90, 2901-2910.
132. Slupianek, A.; Nieborowska-Skorska, M.; Hoser, G.; Morrione, A. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer. Res., 2001, 61, 2194-2199.
133. Tosetti, F.; Ferrari, N.; De, Flora, S.; Albini, A. Angioprevention': Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB. J., 2002, 16, 2-14.
134. Fotsis, T.; Pepper, M. S.; Montesano, R.; Aktas, E.; Breit, S.; Schweigerer, L.; Rasku, S.; Wahala, K.; Adlercreutz, H. Phytoestrogens and inhibition of angiogenesis. Baillieres. Clin. Endocrinol. Metab., 1998, 12, 649-666.
135. Fotsis, T.; Pepper, M.; Adlercreutz, H.; Hase, T.; Montesano, R.; Schweigerer, L. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J. Nutr., 1995, 125, 790-797.
136. Roberts, A. B.; Flanders, K. C.; Heine, U. I.; Jakowlew, S.; Kondaiah, P.; Kim, S. J.; Sporn, M. B. Transforming growth factorbeta: Multifunctional regulator of differentiation and development. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 1990, 327, 145-154.
137. Kim, H.; Peterson, T. G.; Barnes, S. Mechanisms of action of the soy isoflavone genistein: Emerging role for its effects via transforming growth factor beta signaling pathways. Am. J. Clin. Nutr., 1998, 68, 1418-1425.
138. Iwasaki, T.; Mukai, M.; Tsujimura, T.; Tatsuta, M.; Nakamura, H.; Terada, N.; Akedo, H. Involvement of phosphorylation of Tyr-31 and Tyr-118 of paxillin in MM1 cancer cell migration. Int. J. Cancer, 2002, 100, 381-387.
139. Zhou, J. R.; Yu, L.; Zhong, Y.; Nassr, R. L.; Franke, A. A.; Gaston, S. M.; Blackburn, G. L. Inhibition of orthotopic growth and metastasis of androgen-sensitive human prostate tumors in mice by bioactive soybean components. Prostate, 2002, 53, 2, 143-153.
140. Myoung, H.; Hong, S.-P.; Yun, P. Y. Anti-cancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion, Cancer. Sci, 2005, 94, 215-220.
141. Sarkar, F. H.; Adsule, S.; Padhye, S.; Kulkarni, S.; Li, Y. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini-Rev. Med. Chem. 2006, 6, 401-407.
142. Bors, W.; Heller, W.; Michel, C.; Saran, M. Flavonoids as antioxidants: determination of radical-scavenging efficiencies. Methods. Enzymol., 1990, 186, 343-355.
143. Rice-Evans, C. A.; Miller, N. J.; Paganga, G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free. Radic. Biol. Med., 1996, 20, 933-956.
144. Jovanovic, S. V.; Steenken, S.; Hara, Y.; Simic, M. G. Reduction potentials of flavonoid and model phenoxyl radicals. which ring in flavonoids is responsible for antioxidant activity? J. Chem. Soc. Perk. Trans., 1996, 2, 2497-2504.
145. Patole, J.; Dutta, S.; Padhye, S.; Sinn, E. Tuning up superoxide dismutase activity of copper complex of salicylaldehyde semicarbazone by heterocyclic bases pyridine and N-methyl imidazole. Inorg. Chim. Acta, 2001, 318, 207-211.
146. Cabot, M. C.; Yu, J. Y.; Kelly, G. E.; Brown, D. M.; Lucas, K. M.; Tanabe, K.; Allen, J. D. Phenoxodiol, a synthetic analog of genistein, generates ceramide and is equipotent in wild-type and multidrug-resistant human tumor cells. J. Clin. Oncol., 2005, 23, 153-156.
147. Kamsteeg, M.; Rutherford, T.; Sapi, E.; Hanczaruk, B.; Shahabi, S.; Flick, M.; Brown, D.; Mor, G. Phenoxodiol-an isoflavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene, 2003, 22, 2611-2620.
148. Ullmann, U.; Metzner, J.; Frank, T.; Cohn, W.; Riegger, C. Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein™) in healthy volunteers. Adv. Ther., 2005, 22, 65-78.
149. Lania-Pietrzak, B.; Michalak, K.; Hendrich, A. B.; Mosiadz, D.; Grynkiewicz, G.; Motohashi, N.; Shirataki, Y. Modulation of MRP1 protein transport by plant and synthetically modified flavonoids. Life. Sci., 2005, 77,1879-1891.
150. Ullmann, U.; Bendik, I.; Fluhmann, B. BonisteinTM(synthetic genistein), a food component in development for a bone health nutraceutical. J. Physiol. Pharmacol., 2005, 56, 79-84.
151. Barve, V.; Ahmed, F.; Adsule, S. Synthesis, Molecular Characterization, and Biological Activity of Novel Synthetic Derivatives of Chromen-4-one in Human Cancer Cells. J. Med. Chem., 2006, 49, 3800-3808.
152. Kosmider, B.; Osiecka, R. Flavonoid Compounds: A Review of Anticancer Properties and Interactions with cis-Diamminedichloroplatinum(II). Drug. Dev. Res., 2004, 63, 200-211